At ESMO 2024, Josep Llovet, MD, PhD, from the Icahn School of Medicine at Mount Sinai, discusses LEAP-012, which compared TACE alone with pembrolizumab, lenvatinib, and TACE for the treatment of unresectable, non-metastatic hepatocellular carcinoma.
Notable data from this study include: pembrolizumab plus lenvatinib in combination with TACE reduced the risk for disease progression or death by 34% compared to TACE alone, and the median progression-free survival was 14.6 months with the combination versus 10.0 months with TACE alone.
